Filing Details
- Accession Number:
- 0001826466-24-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-19 14:08:45
- Reporting Period:
- 2022-04-13
- Accepted Time:
- 2024-03-19 14:08:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1145604 | Nika Pharmaceuticals Inc | NKPH | Miscellaneous Transportation Equipment (3790) | 900292940 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1145604 | Nika Pharmaceuticals, Inc | 61, Nishava Str., Entr. A, Fl. 3, Apt. 6 Sofia 1680 | President, Ceo, Cfo | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Preferred A Stock | Acquisiton | 2022-04-13 | 10,000,000 | $3,000,000.00 | 10,000,000 | No | 4 | J | Direct | |
Common | Acquisiton | 2022-04-13 | 11,489,000 | $0.01 | 0 | No | 4 | P | Direct | |
Common | Acquisiton | 2022-07-20 | 333,181,000 | $0.00 | 0 | No | 4 | J | Direct | |
Common | Disposition | 2022-09-12 | 7,000,000 | $0.02 | 0 | No | 4 | S | Direct | |
Common | Disposition | 2022-09-26 | 1,250,000 | $0.02 | 0 | No | 4 | S | Direct | |
Common | Disposition | 2022-10-24 | 3,000,000 | $0.04 | 0 | No | 4 | S | Direct | |
Common | Disposition | 2023-01-10 | 6,300,000 | $0.01 | 0 | No | 4 | S | Direct | |
Common | Disposition | 2023-01-31 | 1,500,000 | $0.01 | 0 | No | 4 | S | Direct | |
Common | Disposition | 2023-06-02 | 3,500,000 | $0.02 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | J | Direct | |
No | 4 | P | Direct | |
No | 4 | J | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- Issuance per terms of Exclusive Rights Agreement
- Exclusive rights valued at 3,000,000
- 30-1 forward split as dividend